ethyl 4-(piperidin-4-yloxy)benzoate | 460365-21-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-(piperidin-4-yloxy)benzoate
• 英文别名: Ethyl 4-(4-piperidinyloxy)benzoate；ethyl 4-piperidin-4-yloxybenzoate
• CAS: 460365-21-3
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: JOQPZTQGIMHZOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-(piperidin-4-yloxy)benzoate 、 环戊酮 在 sodium cyanoborohydride 、 zinc(II) chloride 、 甲醇 、 sodium hydroxide 、 水 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  EP1757594

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-butyl 4-(4-ethoxycarbonylphenoxy)piperidine-1-carboxylate 在 三氟乙酸 、 sodium hydroxide 、 水 作用下， 反应 0.5h， 生成 ethyl 4-(piperidin-4-yloxy)benzoate
  参考文献：
  名称：

  EP1757594

  摘要：

  公开号：

文献信息

• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20180099940A1

  公开（公告）日：2018-04-12

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，其用于降解和（抑制）雄激素受体。具体而言，本公开涉及包含一端结合到E3泛素连接酶的谷氨酰腺苷环配体，另一端结合到雄激素受体的部分的化合物，使得雄激素受体与泛素连接酶靠近，以实现雄激素受体的降解（和抑制）。本公开展示了与根据本公开涉及的化合物相关的广泛的药理活性范围，与雄激素受体的降解/抑制一致。
• Compound
  申请人：Toda Ayako

  公开号：US20050261177A1

  公开（公告）日：2005-11-24

  This invention relates to new polypeptide compound represented by the following general formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

  本发明涉及一种由以下一般式（I）表示的新多肽化合物：其中R1、R2、R3、R4、R5和R6如描述中所定义或其盐，具有抗微生物活性（特别是抗真菌活性），抑制β-1,3-葡聚糖合酶的活性，制备其的方法，包含其的药物组合物，以及用于预防和/或治疗包括肺孢子虫感染（例如肺孢子虫肺炎）在内的人类或动物的传染病的方法。
• Quinazoline Derivative
  申请人：Mizutani Takashi

  公开号：US20080275069A1

  公开（公告）日：2008-11-06

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (I) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1代表较低的烷基等；R2和R3相同或不同，分别代表氢原子等；R4代表式（I）的取代基等；X1代表NH、O或S；Y代表N或C；Ar是由芳基衍生的二价取代基等，通过去除其中的两个氢原子而得到；环A表示5-或6-成员杂芳基基团；这些化合物具有组胺H3受体拮抗作用或组胺H3受体反向激动剂作用，并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。
• [EN] NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA<br/>[FR] NOUVEAUX COMPOSÉS APPROPRIÉS POUR LE TRAITEMENT DE LA DYSLIPIDÉMIE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2022130352A1

  公开（公告）日：2022-06-23

  Present invention relates to compounds of general formula (I), their tautomeric forms, stereoisomers, pharmaceutically acceptable salts and pharmaceutical composition containing them. Invention also relates to process for the preparation of compounds of general formula (I) and intermediates thereof. Compounds of present invention can be useful in treating diseases such as hyperlipidemia and other disorders related to hyperlipidemia. Compounds of present invention also have a beneficial effect on lowering cholesterol.

  本发明涉及一般式（I）的化合物，它们的互变异构体，立体异构体，药学上可接受的盐和含有它们的药物组合物。本发明还涉及制备一般式（I）化合物和中间体的过程。本发明的化合物可用于治疗高脂血症等与高脂血症相关的疾病。本发明的化合物还具有降低胆固醇的益处。
• QUINAZOLINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1757594A1

  公开（公告）日：2007-02-28

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R1 represents a lower alkyl group et al; R2 and R3 are same and different and represents hydrogen atm et al; R4 represents the substituent of the formula (II) et al; X1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了一种式 (I) 的化合物或其药学上可接受的盐 其中 R1 代表低级烷基等；R2 和 R3 相同或不同，代表氢大气等；R4 代表式（II）的取代基等； 该化合物具有组胺-H3 受体拮抗作用或组胺-H3 受体反拮抗作用，可用于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病。